Actively Recruiting
The Effect-site Concentration of Remifentanil Blunting Endotracheal Intubation Responses During Anesthesia Induction With Lidocaine or Sufentanil Combined With Etomidate: A Randomized Controlled Study
Led by Peking University Shenzhen Hospital · Updated on 2025-09-22
99
Participants Needed
1
Research Sites
51 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study was to compare the effect-site target concentration (including EC₅₀ and EC₉₀) of remifentanil required to suppress cardiovascular responses to tracheal intubation during anesthesia induction with etomidate combined with either lidocaine or sufentanil.
CONDITIONS
Official Title
The Effect-site Concentration of Remifentanil Blunting Endotracheal Intubation Responses During Anesthesia Induction With Lidocaine or Sufentanil Combined With Etomidate: A Randomized Controlled Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients scheduled for elective surgery under general anesthesia with endotracheal intubation
- Classified as ASA physical status I-II
You will not qualify if you...
- Age less than 18 years or greater than 65 years
- Body mass index (BMI) greater than 30 kg/m6 or less than 18.5 kg/m6
- Diagnosis of hypertension or severe cardiovascular diseases including myocardial infarction, heart failure, atrial fibrillation, atrioventricular block, moderate-to-severe valvular diseases
- Diagnosis of respiratory diseases including acute exacerbation of chronic obstructive pulmonary disease, acute respiratory distress syndrome, acute asthma attack, moderate-to-severe pulmonary hypertension, severe pneumonia
- Diagnosis of obstructive sleep apnea syndrome or history of difficult intubation or preoperatively anticipated difficult airway
- Renal, hepatic or hematologic diseases
- High risk of aspiration or reflux
- Current use of analgesics for chronic pain or beta-blockers for cardiovascular diseases
- Current use of psychotropic medications
- Contraindications to remifentanil or sufentanil such as known hypersensitivity to fentanyl analogues, current use of monoamine oxidase inhibitors, myasthenia gravis or conditions causing respiratory depression, bronchial asthma or related disorders
- Contraindications to lidocaine such as allergy to local anesthetics, concurrent Adams-Stokes syndrome, Wolff-Parkinson-White syndrome, or severe cardiac conduction block
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Actively Recruiting
Research Team
Z
zhencong jiang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here